Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of BGB-16673 vs pirtobrutinib in relapsed/refractory CLL/SLL
jRCT2031250598Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jan 2026
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing BGB-16673 with Pirtobrutinib (2 arms). Primary endpoint: Progression-Free Survival per Independent Review Committee. Started Jan 2026; status: recruiting.
02
Drugs
catadegbrutinibpirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2031250598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250598.